- Record: found
- Abstract: found
- Article: not found
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.
Brian I Rini
1 ,
Susan Halabi ,
Jonathan E Rosenberg ,
Walter M Stadler ,
Daniel A Vaena ,
San-San Ou ,
Laura Archer ,
James N Atkins ,
Joel Picus ,
Piotr Czaykowski ,
Janice Dutcher ,
Eric J Small
Nov 20 2008
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Bevacizumab is an antibody that binds to vascular endothelial growth factor (VEGF) and has activity in metastatic renal cell carcinoma (RCC). Interferon alfa (IFN) is a historic standard first-line treatment for RCC. A prospective, randomized phase III trial of bevacizumab plus IFN versus IFN monotherapy was conducted.